Page last updated: 2024-10-17

phosphonoacetic acid and Herpes Simplex

phosphonoacetic acid has been researched along with Herpes Simplex in 80 studies

Phosphonoacetic Acid: A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent.
phosphonoacetic acid : A member of the class of phosphonic acids that is phosphonic acid in which the hydrogen attached to the phosphorous is replaced by a carboxymethyl group.

Herpes Simplex: A group of acute infections caused by herpes simplex virus type 1 or type 2 that is characterized by the development of one or more small fluid-filled vesicles with a raised erythematous base on the skin or mucous membrane. It occurs as a primary infection or recurs due to a reactivation of a latent infection. (Dorland, 27th ed.)

Research Excerpts

ExcerptRelevanceReference
"Herpes simplex virus (HSV) resistant to acyclovir can produce persistent mucocutaneous ulcerative disease in patients with the acquired immunodeficiency syndrome (AIDS)."9.07Foscarnet treatment of acyclovir-resistant herpes simplex virus infection in patients with acquired immunodeficiency syndrome: preliminary results of a controlled, randomized, regimen-comparative trial. ( Hardy, WD, 1992)
"Acyclovir can prevent the establishment of latent herpes simplex virus (HSV) in sensory ganglia by early treatment of the primary infection in experimental animals."8.76Treatment of experimental latent herpes simplex virus infections with acyclovir and other antiviral compounds. ( Klein, RJ, 1982)
"The role of acyclovir-sensitive herpes simplex virus (HSV) was analyzed in the process of its replacement by a resistant virus in vitro and in vivo in the aspect of acyclovir therapy."7.72Suppression of generation and replication of acyclovir-resistant herpes simplex virus by a sensitive virus. ( Honda, M; Kurokawa, M; Matsuo, K; Niimura, M; Okuda, T; Shiraki, K, 2004)
"Eugeniin exhibits antiviral activity against acyclovir and phosphonoacetic acid (PAA)-resistant herpes simplex virus type 1 (HSV-1) as well as the wild-type HSV-1 in vitro."7.71Biological characterization of eugeniin as an anti-herpes simplex virus type 1 compound in vitro and in vivo. ( Hozumi, T; Kadota, S; Kurokawa, M; Namba, T; Shiraki, K; Tsurita, M, 2001)
"Mucocutaneous herpes simplex virus (HSV) infections that are resistant to therapy with acyclovir have been recognized with increasing frequency in patients with the acquired immunodeficiency syndrome, although alternative therapies in this setting have not been widely studied."7.68Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data. ( Assaykeen, T; Follansbee, S; Mills, J; Safrin, S, 1990)
"Three marrow transplant patients developed pneumonia due to acyclovir-resistant thymidine-kinase-deficient herpes simplex virus (HSV) type 1."7.68Acyclovir-resistant herpes simplex virus causing pneumonia after marrow transplantation. ( Ellis, MN; Hackman, RC; Ljungman, P; Meyers, JD; Shepp, DH, 1990)
"Foscarnet (trisodium phosphonoformate), an investigational pyrophosphate analog increasingly used to treat refractory cytomegalovirus retinitis and mucocutaneous herpes simplex virus infections in immunocompromised patients, has been reported to cause abnormalities in serum calcium and phosphate, including cases of fatal hypocalcemia."7.68Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism. ( Aweeka, FT; Causey, DM; Gambertoglio, JG; Jacobson, MA; Portale, AA, 1991)
"Resistance of herpes simplex virus to acyclovir is a problem of growing clinical importance."7.68Heterogeneity of a herpes simplex virus clinical isolate exhibiting resistance to acyclovir and foscarnet. ( Coen, DM; Hicks, KA; Pelosi, E; Sacks, SL, 1992)
"To determine whether trisodium phosphonoformate (foscarnet) is efficacious in treating severe mucocutaneous disease due to acyclovir-resistant herpes simplex virus type-2 (HSV-2) infection in patients with the acquired immunodeficiency syndrome (AIDS)."7.67Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS). An uncontrolled trial. ( Drennan, DP; Erlich, KS; Follansbee, SE; Gooze, L; Jacobson, MA; Koehler, JE; Mills, J; Safrin, S, 1989)
"Methoxymethyldeoxyuridine (MMUdR) when used in combination with either trifluorothymidine (F3TdR) or phosphonoformate (PFA) showed synergistic activity against herpes simplex virus type 1 and type 2 (HSV-1 and HSV-2) in vitro, whereas MMUdR and acycloguanosine (ACG) combination was antagonistic against herpes viruses."7.67Combination chemotherapy: interaction of 5-methoxymethyldeoxyuridine with trifluorothymidine, phosphonoformate and acycloguanosine against herpes simplex viruses. ( Ayisi, NK; Babiuk, LA; Gupta, SV, 1985)
"Topical foscarnet (PFA) and acyclovir (ACV) were compared in the dorsal cutaneous guinea pig model of herpes simplex virus type 1 infection."7.67Comparison of foscarnet cream, acyclovir cream, and acyclovir ointment in the topical treatment of experimental cutaneous herpes simplex virus type 1 infection. ( Freeman, DJ; Sheth, NV; Spruance, SL, 1986)
"The sensitivity of different herpes simplex virus type 2 (HSV-2) strains to inhibition by 5-vinyl-1-beta-D-arabinofuranosyluracil (VaraU) was evaluated in comparison to 9-(2-hydroxyethoxymethyl)guanine (ACV; acyclovir) and trisodiumphosphonoformate (Na3PFA; foscarnet), using a plaque inhibition assay in primary rabbit testes (PRT) cells as well as in human embryonic lung fibroblast (HELF) cell cultures."7.67Efficacy of 5-vinyl-1-beta-D-arabinofuranosyluracil (VaraU) against herpes simplex virus type 2 strains in cell cultures and against experimental herpes encephalitis in mice: comparison with acyclovir and foscarnet. ( Herrmann, G; Reefschläger, J; Thiel, KD; Wutzler, P, 1987)
"The influence of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU), caffeic acid oxidation product (KOP), and trisodiumphosphonoformate (TPF) on the course of the primary cutaneous herpes simplex virus infection was investigated by means of a guinea pig test model."7.67Therapeutic effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine, caffeic acid oxidation product, and trisodiumphosphonoformate on cutaneous herpes simplex virus type 1 infection in guinea pigs. ( Helbig, B; Herrmann, G; Klöcking, R; Sauerbrei, A; Wicht, N; Wiedemann, U; Wutzler, P, 1987)
"The efficiency of (E)-5-(2-bromovinyl)- and 5-vinyl-1-beta-D-arabinofuranosyluracil (BrVaraU, VaraU) as inhibitors of three herpes simplex virus type 1 (HSV-1) strains was assessed in comparison to (E)-5-(2-bromovinyl)-2'-deoxyuridine (BrVUdR), 9-(2-hydroxyethoxymethyl)guanine (ACV), and trisodium phosphonoformate (Na3PFA) using a plaque assay in human embryonic lung fibroblast (HELF) cell cultures."7.67Treatment of experimental herpes simplex virus type 1 encephalitis in mice with (E)-5-(2-bromovinyl)- and 5-vinyl-1-beta-D-arabinofuranosyluracil: comparison with bromovinyl-deoxyuridine and acyclovir. ( Herrmann, G; Reefschläger, J; Thiel, KD; Wutzler, P, 1986)
"Rapidly progressive disease due to acyclovir-resistant herpes simplex has not been described."7.67Progressive mucocutaneous herpes simplex infection due to acyclovir-resistant virus in an immunocompromised patient: correlation of viral susceptibilities and plasma levels with response to therapy. ( Bean, B; Ellis, MN; Englund, J; Fletcher, C; Lehrman, SN, 1987)
"The inhibition by acyclovir of the in vitro reactivation of herpes simplex virus from latently infected ganglion explant cultures is dependent on the continuous presence of this drug."7.66Effect of acyclovir on latent herpes simplex virus infections in trigeminal ganglia of mice. ( Brady, E; DeStefano, E; Friedman-Kien, AE; Klein, RJ, 1981)
"The antiviral activity of 5-methoxymethyl-2'-deoxyuridine (MMUdR) was compared with that of 5-iodo-2'-deoxyuridine (IUdR), 5-ethyl-2'-deoxyuridine (EtUdR), adenine arabinoside (Ara-A), and phosphonoacetic acid (PAA) against herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2)."7.66Combination chemotherapy: interaction of 5-methoxymethyldeoxyuridine with adenine arabinoside, 5-ethyldeoxyuridine, 5-iododeoxyuridine, and phosphonoacetic acid against herpes simplex virus types 1 and 2. ( Ayisi, NK; Babiuk, LA; Gupta, VS; Meldrum, JB; Taneja, AK, 1980)
"Skin infections induced in hairless mice with an Acyclovir resistant herpes simplex virus (HSV) mutant were not followed by the death of the animals, and the survivors had no evidence of latent infections in their sensory ganglia."7.66Experimental skin infection with an acyclovir resistant herpes simplex virus mutant: response to antiviral treatment and protection against reinfection. ( Brady, E; DeStefano, E; Friedman-Kien, AE; Klein, RJ, 1980)
"The therapeutic effects of topically applied foscarnet sodium and acyclovir on cutaneous infections due to herpes simplex virus type 1 (HSV-1) were studied in guinea pigs."7.66Therapeutic effects of foscarnet sodium and acyclovir on cutaneous infections due to herpes simplex virus type 1 in guinea pigs. ( Alenius, S; Berg, M; Broberg, F; Eklind, K; Lindborg, B; Oberg, B, 1982)
"An acyclovir-resistant herpes simplex virus (HSV) has been isolated from an immunocompromised patient during treatment for severe orofacial HSV infections with acyclovir."7.66Drug-resistant herpes simplex virus in vitro and after acyclovir treatment in an immunocompromised patient. ( Crumpacker, CS; Hershey, BJ; Kowalsky, P; Levin, MJ; Marlowe, SI; Schnipper, LE, 1982)
"Phosphonoacetic acid (PAA) was evaluated as therapy for primary cutaneous herpes simplex virus (HSV) infections in guinea pigs."7.66Topical phosphonoacetic acid treatment of cutaneous herpes simplex infections in the guinea pig. ( Jarratt, MT; McCarty, JR, 1979)
"Virus isolates from four AIDS patients and one bone marrow transplant recipient were examined for their sensitivity for the antiviral compounds used by means of plaque reduction assay."5.28[Acyclovir-resistant herpes simplex virus infections in immunocompromised patients]. ( Frissen, PH; Jansen, CL; Maris-Tegeler, WG; van der Noordaa, J; Weiland, HT; Wertheim-van Dillen, PM, 1992)
"Herpes simplex virus (HSV) resistant to acyclovir can produce persistent mucocutaneous ulcerative disease in patients with the acquired immunodeficiency syndrome (AIDS)."5.07Foscarnet treatment of acyclovir-resistant herpes simplex virus infection in patients with acquired immunodeficiency syndrome: preliminary results of a controlled, randomized, regimen-comparative trial. ( Hardy, WD, 1992)
"Acyclovir can prevent the establishment of latent herpes simplex virus (HSV) in sensory ganglia by early treatment of the primary infection in experimental animals."4.76Treatment of experimental latent herpes simplex virus infections with acyclovir and other antiviral compounds. ( Klein, RJ, 1982)
" A MeOH extract of Symphyocladia latiuscula (Rhodomelaceae) and its fractions exhibited antiviral activities against acyclovir (ACV) and phosphonoacetic acid (PAA)-resistant (AP(r)) herpes simplex type 1 (HSV-1), thymidine kinase (TK(-)) deficient HSV-1 and wild type HSV-1 in vitro without cytotoxicity."3.73Antiviral activity of the marine alga Symphyocladia latiuscula against herpes simplex virus (HSV-1) in vitro and its therapeutic efficacy against HSV-1 infection in mice. ( Choi, JS; Hattori, M; Kurokawa, M; Nakamura, N; Park, HJ; Shiraki, K, 2005)
"The role of acyclovir-sensitive herpes simplex virus (HSV) was analyzed in the process of its replacement by a resistant virus in vitro and in vivo in the aspect of acyclovir therapy."3.72Suppression of generation and replication of acyclovir-resistant herpes simplex virus by a sensitive virus. ( Honda, M; Kurokawa, M; Matsuo, K; Niimura, M; Okuda, T; Shiraki, K, 2004)
"Eugeniin exhibits antiviral activity against acyclovir and phosphonoacetic acid (PAA)-resistant herpes simplex virus type 1 (HSV-1) as well as the wild-type HSV-1 in vitro."3.71Biological characterization of eugeniin as an anti-herpes simplex virus type 1 compound in vitro and in vivo. ( Hozumi, T; Kadota, S; Kurokawa, M; Namba, T; Shiraki, K; Tsurita, M, 2001)
"Mucocutaneous herpes simplex virus (HSV) infections that are resistant to therapy with acyclovir have been recognized with increasing frequency in patients with the acquired immunodeficiency syndrome, although alternative therapies in this setting have not been widely studied."3.68Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data. ( Assaykeen, T; Follansbee, S; Mills, J; Safrin, S, 1990)
"Three AIDS patients with severe cutaneous herpes simplex virus (HSV) infection refractory to therapy with acyclovir and foscarnet (2 patients) were treated with a topical preparation of trifluorothymidine (TFT) and interferon-alpha."3.68Clinical effects and in vitro studies of trifluorothymidine combined with interferon-alpha for treatment of drug-resistant and -sensitive herpes simplex virus infections. ( Birch, CJ; Doherty, R; Hayes, K; Lucas, CR; Mijch, A; Tachedjian, G; Tyssen, DP, 1992)
"Three marrow transplant patients developed pneumonia due to acyclovir-resistant thymidine-kinase-deficient herpes simplex virus (HSV) type 1."3.68Acyclovir-resistant herpes simplex virus causing pneumonia after marrow transplantation. ( Ellis, MN; Hackman, RC; Ljungman, P; Meyers, JD; Shepp, DH, 1990)
"Acyclovir (ACV)-resistant herpes simplex virus type 2 (HSV-2) was isolated from a patient with acquired immunodeficiency syndrome after long-term but intermittent ACV therapy."3.68Altered sensitivity to antiviral drugs of herpes simplex virus isolates from a patient with the acquired immunodeficiency syndrome. ( Birch, CJ; Doherty, RR; Gust, ID; Hayes, K; Tachedjian, G, 1990)
"Foscarnet (trisodium phosphonoformate), an investigational pyrophosphate analog increasingly used to treat refractory cytomegalovirus retinitis and mucocutaneous herpes simplex virus infections in immunocompromised patients, has been reported to cause abnormalities in serum calcium and phosphate, including cases of fatal hypocalcemia."3.68Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism. ( Aweeka, FT; Causey, DM; Gambertoglio, JG; Jacobson, MA; Portale, AA, 1991)
"Resistance of herpes simplex virus to acyclovir is a problem of growing clinical importance."3.68Heterogeneity of a herpes simplex virus clinical isolate exhibiting resistance to acyclovir and foscarnet. ( Coen, DM; Hicks, KA; Pelosi, E; Sacks, SL, 1992)
"The herpesvirus DNA polymerase inhibitor foscarnet, applied topically, and the anti-herpesvirus guanosine analogue buciclovir, given orally, decreased virus replication and disease development in primary skin infections of mice caused by herpes simplex virus type 1 (HSV-1)."3.67Limited efficacy of inhibitors of herpes simplex virus DNA synthesis in murine models of recrudescent disease. ( Datema, R; Ericson, AC; Kristofferson, A; Sohl-Akerlund, A, 1988)
"The sensitivity of different herpes simplex virus type 2 (HSV-2) strains to inhibition by 5-vinyl-1-beta-D-arabinofuranosyluracil (VaraU) was evaluated in comparison to 9-(2-hydroxyethoxymethyl)guanine (ACV; acyclovir) and trisodiumphosphonoformate (Na3PFA; foscarnet), using a plaque inhibition assay in primary rabbit testes (PRT) cells as well as in human embryonic lung fibroblast (HELF) cell cultures."3.67Efficacy of 5-vinyl-1-beta-D-arabinofuranosyluracil (VaraU) against herpes simplex virus type 2 strains in cell cultures and against experimental herpes encephalitis in mice: comparison with acyclovir and foscarnet. ( Herrmann, G; Reefschläger, J; Thiel, KD; Wutzler, P, 1987)
"Topical foscarnet (PFA) and acyclovir (ACV) were compared in the dorsal cutaneous guinea pig model of herpes simplex virus type 1 infection."3.67Comparison of foscarnet cream, acyclovir cream, and acyclovir ointment in the topical treatment of experimental cutaneous herpes simplex virus type 1 infection. ( Freeman, DJ; Sheth, NV; Spruance, SL, 1986)
"The influence of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU), caffeic acid oxidation product (KOP), and trisodiumphosphonoformate (TPF) on the course of the primary cutaneous herpes simplex virus infection was investigated by means of a guinea pig test model."3.67Therapeutic effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine, caffeic acid oxidation product, and trisodiumphosphonoformate on cutaneous herpes simplex virus type 1 infection in guinea pigs. ( Helbig, B; Herrmann, G; Klöcking, R; Sauerbrei, A; Wicht, N; Wiedemann, U; Wutzler, P, 1987)
"Methoxymethyldeoxyuridine (MMUdR) when used in combination with either trifluorothymidine (F3TdR) or phosphonoformate (PFA) showed synergistic activity against herpes simplex virus type 1 and type 2 (HSV-1 and HSV-2) in vitro, whereas MMUdR and acycloguanosine (ACG) combination was antagonistic against herpes viruses."3.67Combination chemotherapy: interaction of 5-methoxymethyldeoxyuridine with trifluorothymidine, phosphonoformate and acycloguanosine against herpes simplex viruses. ( Ayisi, NK; Babiuk, LA; Gupta, SV, 1985)
"Several 5-methoxymethyldeoxyuridine (MMdU)-resistant mutants of herpes simplex virus type 1 (HSV1) were classified by measuring their sensitivities to the deoxythymidine kinase (dTK)-dependent antiviral drugs 9-(2-hydroxyethoxymethyl)-guanine (acyclovir, ACV), 1-beta-D-arabinofuranosylthymine (araT), and E-(2)-5-bromovinyldeoxyuridine (BVdU) and to the dTK-independent antiviral drug phosphonoacetate (PAA)."3.67HSV1-specific thymidylate kinase activity in infected cells. ( Gentry, GA; Veerisetty, V, 1985)
"The efficiency of (E)-5-(2-bromovinyl)- and 5-vinyl-1-beta-D-arabinofuranosyluracil (BrVaraU, VaraU) as inhibitors of three herpes simplex virus type 1 (HSV-1) strains was assessed in comparison to (E)-5-(2-bromovinyl)-2'-deoxyuridine (BrVUdR), 9-(2-hydroxyethoxymethyl)guanine (ACV), and trisodium phosphonoformate (Na3PFA) using a plaque assay in human embryonic lung fibroblast (HELF) cell cultures."3.67Treatment of experimental herpes simplex virus type 1 encephalitis in mice with (E)-5-(2-bromovinyl)- and 5-vinyl-1-beta-D-arabinofuranosyluracil: comparison with bromovinyl-deoxyuridine and acyclovir. ( Herrmann, G; Reefschläger, J; Thiel, KD; Wutzler, P, 1986)
"To determine whether trisodium phosphonoformate (foscarnet) is efficacious in treating severe mucocutaneous disease due to acyclovir-resistant herpes simplex virus type-2 (HSV-2) infection in patients with the acquired immunodeficiency syndrome (AIDS)."3.67Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS). An uncontrolled trial. ( Drennan, DP; Erlich, KS; Follansbee, SE; Gooze, L; Jacobson, MA; Koehler, JE; Mills, J; Safrin, S, 1989)
"Rapidly progressive disease due to acyclovir-resistant herpes simplex has not been described."3.67Progressive mucocutaneous herpes simplex infection due to acyclovir-resistant virus in an immunocompromised patient: correlation of viral susceptibilities and plasma levels with response to therapy. ( Bean, B; Ellis, MN; Englund, J; Fletcher, C; Lehrman, SN, 1987)
"The antiviral activity of 5-methoxymethyl-2'-deoxyuridine (MMUdR) was compared with that of 5-iodo-2'-deoxyuridine (IUdR), 5-ethyl-2'-deoxyuridine (EtUdR), adenine arabinoside (Ara-A), and phosphonoacetic acid (PAA) against herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2)."3.66Combination chemotherapy: interaction of 5-methoxymethyldeoxyuridine with adenine arabinoside, 5-ethyldeoxyuridine, 5-iododeoxyuridine, and phosphonoacetic acid against herpes simplex virus types 1 and 2. ( Ayisi, NK; Babiuk, LA; Gupta, VS; Meldrum, JB; Taneja, AK, 1980)
"Skin infections induced in hairless mice with an Acyclovir resistant herpes simplex virus (HSV) mutant were not followed by the death of the animals, and the survivors had no evidence of latent infections in their sensory ganglia."3.66Experimental skin infection with an acyclovir resistant herpes simplex virus mutant: response to antiviral treatment and protection against reinfection. ( Brady, E; DeStefano, E; Friedman-Kien, AE; Klein, RJ, 1980)
"The inhibition by acyclovir of the in vitro reactivation of herpes simplex virus from latently infected ganglion explant cultures is dependent on the continuous presence of this drug."3.66Effect of acyclovir on latent herpes simplex virus infections in trigeminal ganglia of mice. ( Brady, E; DeStefano, E; Friedman-Kien, AE; Klein, RJ, 1981)
"The comparative analysis of the pathogenicity of a parental herpes simplex virus type 1 strain and its phosphonoacetic acid (PAA)-resistant and acyclovir (ACV)-resistant mutants showed marked differences among them."3.66Pathogenesis of experimental skin infections induced by drug-resistant herpes simplex virus mutants. ( DeStefano, E; Friedman-Kien, AE; Klein, RJ, 1981)
"The therapeutic effects of topically applied foscarnet sodium and acyclovir on cutaneous infections due to herpes simplex virus type 1 (HSV-1) were studied in guinea pigs."3.66Therapeutic effects of foscarnet sodium and acyclovir on cutaneous infections due to herpes simplex virus type 1 in guinea pigs. ( Alenius, S; Berg, M; Broberg, F; Eklind, K; Lindborg, B; Oberg, B, 1982)
"Phosphonoacetic acid (PAA) was evaluated as therapy for primary cutaneous herpes simplex virus (HSV) infections in guinea pigs."3.66Topical phosphonoacetic acid treatment of cutaneous herpes simplex infections in the guinea pig. ( Jarratt, MT; McCarty, JR, 1979)
"An acyclovir-resistant herpes simplex virus (HSV) has been isolated from an immunocompromised patient during treatment for severe orofacial HSV infections with acyclovir."3.66Drug-resistant herpes simplex virus in vitro and after acyclovir treatment in an immunocompromised patient. ( Crumpacker, CS; Hershey, BJ; Kowalsky, P; Levin, MJ; Marlowe, SI; Schnipper, LE, 1982)
" These questions concern appropriate routes of administration for antiviral compounds, optimal dosage regimens, risks of long-term prophylaxis, and the emergence of resistant organisms."2.66Antiviral chemotherapy and chemoprophylaxis. ( Dolin, R, 1985)
" Myelosuppression may be further exacerbated in AIDS patients by such other agents as zidovudine or trimethoprim/sulfamethoxazole, often necessitating dosage reductions or discontinuation of these agents in patients receiving ganciclovir."2.38Foscarnet sodium. ( Baltz, JK; Minor, JR, 1991)
"Acyclovir is a prototype of this improved process."2.37Promising new antiviral drugs. ( Bryson, YJ, 1988)
"The mechanism of recurrence is yet not fully elucidated and therapy still remains a problem."2.36[Herpes simplex]. ( Fanta, D, 1981)
"Virus isolates from four AIDS patients and one bone marrow transplant recipient were examined for their sensitivity for the antiviral compounds used by means of plaque reduction assay."1.28[Acyclovir-resistant herpes simplex virus infections in immunocompromised patients]. ( Frissen, PH; Jansen, CL; Maris-Tegeler, WG; van der Noordaa, J; Weiland, HT; Wertheim-van Dillen, PM, 1992)
"Phosphonoacetic acid is a selective antiherpesvirus agent."1.27Structure-activity studies on phosphonoacetate. ( Duff, RG; Fairgrieve, JS; Herrin, TR; Mao, JC; Otis, ER; Shipkowitz, NL; von Esch, AM, 1985)
" The dosage of Foscarnet was increased during the study."1.27Clinical experiences with phosphonoformate (foscarnet) treatment of viral diseases following renal transplantation. ( Ahlmén, J; Brynger, H; Lycke, E; Wijnween, AC, 1985)
"Phosphonoacetic acid was the only compound with a good therapeutic activity against herpesvirus infection, causing a reduction of both the cumulative score and the time to healing."1.26Comparison of the therapeutic effects of five antiviral agents on cutaneous herpesvirus infection in guinea pigs. ( Alenius, S; Oberg, B, 1978)
"Phosphonoacetic acid was highly effective in preventing the development of skin lesions, and no latent infections were detected when phosphonoacetic acid ointment was applied 3 h after infection."1.26Orofacial herpes simplex virus infection in hairless mice: latent virus in trigeminal ganglia after topical antiviral treatment. ( Friedman-Kien, AE; Klein, RJ; Yellin, PB, 1978)

Research

Studies (80)

TimeframeStudies, this research(%)All Research%
pre-199050 (62.50)18.7374
1990's22 (27.50)18.2507
2000's6 (7.50)29.6817
2010's2 (2.50)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Griengl, H1
Hayden, W1
Penn, G1
De Clercq, E1
Rosenwirth, B1
Diana, GD1
Carabateas, PM1
Williams, GL1
Pancic, F1
Steinberg, BA1
Schmidt, N1
Hennig, T1
Serwa, RA1
Marchetti, M1
O'Hare, P1
Millhouse, S1
Wang, X1
Fraser, NW2
Faber, L1
Block, TM1
Okuda, T1
Kurokawa, M4
Matsuo, K1
Honda, M1
Niimura, M1
Shiraki, K4
Lipipun, V1
Suttisri, R1
Taweechotipatr, P1
Pramyothin, P1
Hattori, M2
Park, HJ1
Nakamura, N1
Choi, JS1
Yamamoto, S1
Deckter, LA1
Kasai, K1
Chiocca, EA1
Saeki, Y1
Yamauchi, Y1
Kiriyama, K1
Kimura, H1
Nishiyama, Y2
Poryo, A1
Wigand, R2
Burkhardt, U1
Svennerholm, B2
Ziegler, R1
Lycke, E3
Blohmé, I1
Ahlmén, J2
Jeansson, S1
Ranch, T1
Brynger, H2
Ayisi, NK2
Gupta, VS1
Meldrum, JB1
Taneja, AK1
Babiuk, LA2
Klein, RJ6
DeStefano, E3
Brady, E3
Friedman-Kien, AE5
Alenius, S3
Scriba, M1
Rapp, F2
Vahlne, A1
Berg, M1
Broberg, F1
Eklind, K1
Lindborg, B1
Oberg, B2
Fanta, D1
Schnipper, LE1
Crumpacker, CS2
Marlowe, SI1
Kowalsky, P1
Hershey, BJ1
Levin, MJ1
Edwards, ML1
Ritter, HW1
Stemerick, DM1
Stewart, KT1
Hozumi, T1
Tsurita, M1
Kadota, S1
Namba, T1
St Geme, JW1
Yellin, PB1
Wohlenberg, C1
Openshaw, H1
Notkins, AL1
Cho, CT1
Feng, KK1
Palmer, AE1
London, WT1
Sever, JL1
Colberg-Poley, AM1
Isom, H1
McCarty, JR1
Jarratt, MT1
Streissle, G1
Masur, H1
Jansen, CL1
Maris-Tegeler, WG1
Wertheim-van Dillen, PM1
Frissen, PH2
Weiland, HT1
van der Noordaa, J1
Birch, CJ2
Tyssen, DP1
Tachedjian, G2
Doherty, R1
Hayes, K2
Mijch, A1
Lucas, CR1
Cotte, L1
Langlois, M1
Trepo, C1
Yirrell, DL2
Rogers, CE2
Blyth, WA2
Hill, TJ2
Pelosi, E1
Hicks, KA1
Sacks, SL1
Coen, DM1
Molina, JM1
David, F1
Scieux, C1
Schnell, L1
Gerrier, F1
Kateb, M1
Morinet, F1
Modai, J1
Hardy, WD1
Arao, Y1
Hatano, A1
Yamada, M1
Uno, F1
Nii, S1
Moeland, A1
Bruun, JN1
Arbesfeld, DM1
Thomas, I1
Jacobson, MA2
Gambertoglio, JG1
Aweeka, FT1
Causey, DM1
Portale, AA1
Stellbrink, HJ1
Albrecht, H1
Löning, T1
Greten, H1
Bevilacqua, F1
Marcello, A1
Toni, M1
Zavattoni, M1
Cusini, M1
Zerboni, R1
Gerna, G1
Palù, G1
Minor, JR1
Baltz, JK1
Van Der Pijl, JW1
Reiss, P1
Hulsebosch, HJ1
Van Den Tweel, JG1
Lange, JM1
Danner, SA1
Charmot, G1
Ingrand, D1
Simon, F1
Kernbaum, S1
Fegueux, S1
De Truchis, P1
Coulaud, JP1
Safrin, S2
Assaykeen, T1
Follansbee, S1
Mills, J3
Ljungman, P1
Ellis, MN2
Hackman, RC1
Shepp, DH1
Meyers, JD1
Doherty, RR1
Gust, ID1
Bryson, YJ1
Erlich, KS1
Koehler, JE1
Follansbee, SE1
Drennan, DP2
Gooze, L1
MacPhail, LA1
Greenspan, D1
Schiødt, M1
Chatis, PA1
Miller, CH1
Schrager, LE1
Bean, B1
Fletcher, C1
Englund, J1
Lehrman, SN1
Helbig, B1
Sauerbrei, A1
Klöcking, R1
Wutzler, P4
Wicht, N1
Wiedemann, U1
Herrmann, G3
Spivack, JG1
Kristofferson, A1
Ericson, AC2
Sohl-Akerlund, A1
Datema, R2
Reefschläger, J2
Thiel, KD2
Ulbricht, A1
Färber, I1
Spruance, SL1
Freeman, DJ1
Sheth, NV1
van Genderen, J1
Wolthuis, OL1
Ariens, AT1
Dolin, R1
Mao, JC1
Otis, ER1
von Esch, AM1
Herrin, TR1
Fairgrieve, JS1
Shipkowitz, NL1
Duff, RG1
Gupta, SV1
Veerisetty, V1
Gentry, GA1
Larder, BA1
Darby, G1
Wijnween, AC1
Hall, MJ1
Harmenberg, J1
Abele, G1
Wahren, B1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure[NCT00000691]Phase 2156 participants InterventionalCompleted
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

7 reviews available for phosphonoacetic acid and Herpes Simplex

ArticleYear
[Herpes simplex].
    Wiener klinische Wochenschrift, 1981, Dec-25, Volume: 93, Issue:24

    Topics: Adolescent; Adult; Amantadine; Antigens, Viral; Cell Transformation, Viral; Female; Foscarnet; Herpe

1981
Treatment of experimental latent herpes simplex virus infections with acyclovir and other antiviral compounds.
    The American journal of medicine, 1982, Jul-20, Volume: 73, Issue:1A

    Topics: Acyclovir; Animals; Antiviral Agents; Culture Techniques; Foscarnet; Ganglia; Guanine; Herpes Simple

1982
Therapeutic control of viral infections: chemotherapy, interferon and gamma globulin.
    Current problems in pediatrics, 1979, Volume: 10, Issue:1

    Topics: Amantadine; Animals; Benzimidazoles; Chickenpox; Cytarabine; gamma-Globulins; Hepatitis, Viral, Huma

1979
[Treatment of herpesvirus infections].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1991, Sep-20, Volume: 111, Issue:22

    Topics: Acyclovir; Antiviral Agents; Cytomegalovirus Infections; Drug Resistance, Microbial; Foscarnet; Ganc

1991
Cutaneous herpes simplex virus infections.
    American family physician, 1991, Volume: 43, Issue:5

    Topics: Acyclovir; Administration, Oral; Antiviral Agents; Diagnosis, Differential; Drug Resistance, Microbi

1991
Foscarnet sodium.
    DICP : the annals of pharmacotherapy, 1991, Volume: 25, Issue:1

    Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi

1991
Promising new antiviral drugs.
    Journal of the American Academy of Dermatology, 1988, Volume: 18, Issue:1 Pt 2

    Topics: Acyclovir; Animals; Antiviral Agents; Bromodeoxyuridine; Cytomegalovirus Infections; Foscarnet; Ganc

1988

Trials

2 trials available for phosphonoacetic acid and Herpes Simplex

ArticleYear
Foscarnet treatment of acyclovir-resistant herpes simplex virus infection in patients with acquired immunodeficiency syndrome: preliminary results of a controlled, randomized, regimen-comparative trial.
    The American journal of medicine, 1992, Feb-14, Volume: 92, Issue:2A

    Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Drug Resistance, Microbial; Foscarn

1992
Antiviral chemotherapy and chemoprophylaxis.
    Science (New York, N.Y.), 1985, Mar-15, Volume: 227, Issue:4692

    Topics: Acyclovir; Adult; Aged; Amantadine; Antiviral Agents; Chickenpox; Clinical Trials as Topic; Cytomega

1985

Other Studies

71 other studies available for phosphonoacetic acid and Herpes Simplex

ArticleYear
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
    Journal of medicinal chemistry, 1988, Volume: 31, Issue:9

    Topics: Animals; Antiviral Agents; Bromodeoxyuridine; Cell Line; Chemical Phenomena; Chemistry; Deoxyuridine

1988
Synthesis and antiherpetic activity of some 4-[(aryloxy)alkyl]pyrazoles.
    Journal of medicinal chemistry, 1981, Volume: 24, Issue:6

    Topics: Animals; Anisoles; Antiviral Agents; Female; Herpes Simplex; Mice; Phenyl Ethers; Pyrazoles; Simplex

1981
Remote Activation of Host Cell DNA Synthesis in Uninfected Cells Signaled by Infected Cells in Advance of Virus Transmission.
    Journal of virology, 2015, Volume: 89, Issue:21

    Topics: Animals; Azides; Bacterial Proteins; Cell Line; Chlorocebus aethiops; DNA Replication; Herpes Simple

2015
Direct evidence that HSV DNA damaged by ultraviolet (UV) irradiation can be repaired in a cell type-dependent manner.
    Journal of neurovirology, 2012, Volume: 18, Issue:3

    Topics: Animals; Chlorocebus aethiops; DNA Damage; DNA Repair; DNA-Directed DNA Polymerase; DNA, Viral; Enzy

2012
Suppression of generation and replication of acyclovir-resistant herpes simplex virus by a sensitive virus.
    Journal of medical virology, 2004, Volume: 72, Issue:1

    Topics: Acyclovir; Animals; Antiviral Agents; Chlorocebus aethiops; Drug Resistance, Viral; Female; Herpes S

2004
Efficacy of Thai medicinal plant extracts against herpes simplex virus type 1 infection in vitro and in vivo.
    Antiviral research, 2003, Volume: 60, Issue:3

    Topics: Animals; Antiviral Agents; Chlorocebus aethiops; Drug Resistance, Viral; Herpes Simplex; Herpesvirus

2003
Antiviral activity of the marine alga Symphyocladia latiuscula against herpes simplex virus (HSV-1) in vitro and its therapeutic efficacy against HSV-1 infection in mice.
    Biological & pharmaceutical bulletin, 2005, Volume: 28, Issue:12

    Topics: Acyclovir; Administration, Oral; Animals; Antiviral Agents; Brain; Chlorocebus aethiops; Disease Mod

2005
Imaging immediate-early and strict-late promoter activity during oncolytic herpes simplex virus type 1 infection and replication in tumors.
    Gene therapy, 2006, Volume: 13, Issue:24

    Topics: Animals; Antiviral Agents; Cell Line; Chlorocebus aethiops; Gene Expression; Genetic Engineering; Ge

2006
Herpes simplex virus induces extensive modification and dynamic relocalisation of the nuclear mitotic apparatus (NuMA) protein in interphase cells.
    Journal of cell science, 2008, Jun-15, Volume: 121, Issue:Pt 12

    Topics: Animals; Antigens, Nuclear; Cell Cycle Proteins; Cell Line, Tumor; Chlorocebus aethiops; DNA-Directe

2008
Cutaneous herpes simplex virus infection of the guinea pig: lack of resistance to acyclovir and phosphonoformic acid after topical treatment.
    Medical microbiology and immunology, 1984, Volume: 173, Issue:4

    Topics: Acyclovir; Administration, Topical; Animals; Drug Resistance, Microbial; Drug Therapy, Combination;

1984
Combined chemotherapy of cutaneous herpes simplex infection of the guinea pig.
    Journal of medical virology, 1983, Volume: 12, Issue:2

    Topics: Acyclovir; Animals; Antiviral Agents; Arabinonucleosides; Deoxyuridine; Drug Therapy, Combination; F

1983
Neuritic uptake and transport of antiviral drugs modifying herpes simplex virus infection of rat sensory neurons.
    Archives of virology, 1984, Volume: 81, Issue:3-4

    Topics: Acyclovir; Animals; Antigens, Viral; Biological Transport; Cells, Cultured; Female; Foscarnet; Gangl

1984
Disseminating herpes simplex infection: primary lesions in urinary bladder and successful treatment with forscarnet sodium.
    Transplantation proceedings, 1984, Volume: 16, Issue:6

    Topics: Adult; Female; Foscarnet; Herpes Simplex; Humans; Kidney Transplantation; Organophosphorus Compounds

1984
Combination chemotherapy: interaction of 5-methoxymethyldeoxyuridine with adenine arabinoside, 5-ethyldeoxyuridine, 5-iododeoxyuridine, and phosphonoacetic acid against herpes simplex virus types 1 and 2.
    Antimicrobial agents and chemotherapy, 1980, Volume: 17, Issue:4

    Topics: Animals; Antiviral Agents; Deoxyuridine; Dose-Response Relationship, Drug; Drug Resistance, Microbia

1980
Experimental skin infection with an acyclovir resistant herpes simplex virus mutant: response to antiviral treatment and protection against reinfection.
    Archives of virology, 1980, Volume: 65, Issue:3-4

    Topics: Acyclovir; Animals; Drug Resistance, Microbial; Female; Ganglia; Guanine; Herpes Simplex; Mice; Mice

1980
Inhibition of herpesvirus multiplication in guinea pig skin by antiviral compounds.
    Archives of virology, 1980, Volume: 65, Issue:2

    Topics: Animals; Antiviral Agents; Cytarabine; Foscarnet; Guinea Pigs; Herpes Simplex; Idoxuridine; Male; Or

1980
Persistence of herpes simplex virus (HSV) infection in ganglia and peripheral tissues of guinea pigs.
    Medical microbiology and immunology, 1981, Volume: 169, Issue:2

    Topics: Animals; Denervation; Female; Ganglia; Ganglia, Spinal; Guinea Pigs; Herpes Simplex; Phosphonoacetic

1981
Repair replication of viral and cellular DNA in herpes simplex virus type 2-infected human embryonic and xeroderma pigmentosum cells.
    Virology, 1981, Apr-30, Volume: 110, Issue:2

    Topics: Cells, Cultured; DNA Repair; DNA Replication; DNA, Viral; Herpes Simplex; Humans; Phosphonoacetic Ac

1981
Effect of acyclovir on latent herpes simplex virus infections in trigeminal ganglia of mice.
    Antimicrobial agents and chemotherapy, 1981, Volume: 19, Issue:5

    Topics: Acyclovir; Animals; Antiviral Agents; Culture Techniques; Guanine; Herpes Simplex; Mice; Mice, Hairl

1981
Persistent reactivable latent herpes simplex virus infection in trigeminal ganglia of mice treated with antiviral drugs.
    Archives of virology, 1981, Volume: 69, Issue:1

    Topics: Acyclovir; Animals; Antiviral Agents; Foscarnet; Guanine; Herpes Simplex; Idoxuridine; Male; Mice; M

1981
Pathogenesis of experimental skin infections induced by drug-resistant herpes simplex virus mutants.
    Infection and immunity, 1981, Volume: 34, Issue:3

    Topics: Acyclovir; Animals; Antibodies, Viral; Drug Resistance, Microbial; Female; Guanine; Herpes Simplex;

1981
Therapeutic effects of foscarnet sodium and acyclovir on cutaneous infections due to herpes simplex virus type 1 in guinea pigs.
    The Journal of infectious diseases, 1982, Volume: 145, Issue:4

    Topics: Acyclovir; Administration, Topical; Animals; Dose-Response Relationship, Drug; Foscarnet; Guanine; G

1982
Drug-resistant herpes simplex virus in vitro and after acyclovir treatment in an immunocompromised patient.
    The American journal of medicine, 1982, Jul-20, Volume: 73, Issue:1A

    Topics: Acyclovir; Antiviral Agents; DNA-Directed DNA Polymerase; Drug Resistance, Microbial; Guanine; Herpe

1982
Mannich bases of 4-phenyl-3-buten-2-one: a new class of antiherpes agent.
    Journal of medicinal chemistry, 1983, Volume: 26, Issue:3

    Topics: Amines; Animals; Butanones; Dose-Response Relationship, Drug; Herpes Simplex; Mannich Bases; Mice; M

1983
Biological characterization of eugeniin as an anti-herpes simplex virus type 1 compound in vitro and in vivo.
    The Journal of pharmacology and experimental therapeutics, 2001, Volume: 297, Issue:1

    Topics: Acyclovir; Animals; Antiviral Agents; Brain; Female; Gallic Acid; Glucosides; Herpes Simplex; Herpes

2001
Latent herpes simplex virus in ganglia of mice after primary infection and reinoculation at a distant site.
    Archives of virology, 1978, Volume: 57, Issue:2

    Topics: Animals; Antibodies, Viral; Central Nervous System Diseases; Ganglia; Ganglia, Spinal; Herpes Simple

1978
Orofacial herpes simplex virus infection in hairless mice: latent virus in trigeminal ganglia after topical antiviral treatment.
    Infection and immunity, 1978, Volume: 20, Issue:1

    Topics: Administration, Topical; Animals; Antibodies, Viral; Facial Dermatoses; Herpes Simplex; Mice; Mice,

1978
In vitro system for studying the efficacy of antiviral agents in preventing the reactivation of latent herpes simplex virus.
    Antimicrobial agents and chemotherapy, 1979, Volume: 15, Issue:4

    Topics: Animals; Antibodies, Viral; Antiviral Agents; Female; Ganglia; Herpes Simplex; Interferons; Mice; Mi

1979
Synergistic effects of antiviral agents and humoral antibodies in experimental Herpesvirus hominis encephalitis.
    Annals of the New York Academy of Sciences, 1977, Mar-04, Volume: 284

    Topics: Animals; Antibodies, Viral; Antiviral Agents; Brain; Dose-Response Relationship, Drug; Encephalitis;

1977
Disodium phosphonoacetate in cream base as a possible topical treatment for skin lesions of herpes simplex virus in cebus monkeys.
    Antimicrobial agents and chemotherapy, 1977, Volume: 12, Issue:4

    Topics: Animals; Haplorhini; Herpes Simplex; Ointments; Organophosphorus Compounds; Phosphonoacetic Acid; Pl

1977
Experimental HSV latency using phosphonoacetic acid.
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1979, Volume: 162, Issue:1

    Topics: Cells, Cultured; DNA, Viral; Embryo, Mammalian; Herpes Simplex; Humans; Lung; Organophosphorus Compo

1979
Topical phosphonoacetic acid treatment of cutaneous herpes simplex infections in the guinea pig.
    Journal of the American Academy of Dermatology, 1979, Volume: 1, Issue:3

    Topics: Animals; Croton Oil; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Guinea Pigs; Herp

1979
Comparative evaluation of antiherpetic drugs in animal experiments.
    Advances in ophthalmology = Fortschritte der Augenheilkunde = Progres en ophtalmologie, 1979, Volume: 38

    Topics: Animals; Brain Diseases; Disease Models, Animal; Evaluation Studies as Topic; Herpes Simplex; Immuno

1979
Comparison of the therapeutic effects of five antiviral agents on cutaneous herpesvirus infection in guinea pigs.
    Archives of virology, 1978, Volume: 58, Issue:4

    Topics: Animals; Antiviral Agents; Cytarabine; Guinea Pigs; Herpes Simplex; Idoxuridine; Phosphonoacetic Aci

1978
Clinical implications of herpesvirus infections in patients with AIDS. Introduction.
    The American journal of medicine, 1992, Feb-14, Volume: 92, Issue:2A

    Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi

1992
[Acyclovir-resistant herpes simplex virus infections in immunocompromised patients].
    Nederlands tijdschrift voor geneeskunde, 1992, Feb-08, Volume: 136, Issue:6

    Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Bone Transplantation; Drug R

1992
Clinical effects and in vitro studies of trifluorothymidine combined with interferon-alpha for treatment of drug-resistant and -sensitive herpes simplex virus infections.
    The Journal of infectious diseases, 1992, Volume: 166, Issue:1

    Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Combined Modality Therapy; C

1992
Herpes simplex virus infection during foscarnet therapy.
    The Journal of infectious diseases, 1992, Volume: 166, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet;

1992
Experimental in vivo generation of intertypic recombinant strains of HSV in the mouse.
    Archives of virology, 1992, Volume: 125, Issue:1-4

    Topics: Animals; Female; Foscarnet; Ganglia, Sympathetic; Herpes Simplex; Mice; Mice, Inbred Strains; Phosph

1992
Heterogeneity of a herpes simplex virus clinical isolate exhibiting resistance to acyclovir and foscarnet.
    Advances in experimental medicine and biology, 1992, Volume: 312

    Topics: Acyclovir; Animals; Drug Resistance, Microbial; Foscarnet; Genetic Variation; Herpes Simplex; Humans

1992
[Type 1 herpesvirus cutaneo-mucous infection resistant to aciclovir in a HIV infected patient. Clinical and virological study].
    Annales de medecine interne, 1992, Volume: 143, Issue:3

    Topics: Acyclovir; Adult; Antiviral Agents; Drug Resistance, Microbial; Foscarnet; Herpes Simplex; HIV Infec

1992
Reactivatable latency of three avirulent strains of herpes simplex virus type 1 after intranasal inoculation in mice.
    Acta medica Okayama, 1991, Volume: 45, Issue:1

    Topics: Acyclovir; Administration, Intranasal; Animals; Butyrates; Butyric Acid; Herpes Simplex; Mice; Phosp

1991
Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism.
    The Journal of clinical endocrinology and metabolism, 1991, Volume: 72, Issue:5

    Topics: Antiviral Agents; Calcium; Dose-Response Relationship, Drug; Foscarnet; Herpes Simplex; Humans; Hypo

1991
Herpes simplex virus type-2 ulcers resistant to acyclovir in an AIDS patient--successful treatment with foscarnet.
    Klinische Wochenschrift, 1991, Apr-04, Volume: 69, Issue:6

    Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Anus Diseases; Drug Resistan

1991
Acyclovir resistance/susceptibility in herpes simplex virus type 2 sequential isolates from an AIDS patient.
    Journal of acquired immune deficiency syndromes, 1991, Volume: 4, Issue:10

    Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Drug Resistance, Microbial; Follow-Up Studies;

1991
Foscarnet effective in acyclovir-resistant herpes.
    American pharmacy, 1991, Volume: NS31, Issue:11

    Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Drug Resistance, Microbial; Foscarn

1991
Foscarnet and penile ulceration.
    Lancet (London, England), 1990, Feb-03, Volume: 335, Issue:8684

    Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Herpes

1990
[Aciclovir-resistant herpes simplex virus infection in an immuno-depressed patient. Favourable effect of foscarnet].
    Presse medicale (Paris, France : 1983), 1990, Dec-01, Volume: 19, Issue:41

    Topics: Acyclovir; Antiviral Agents; Drug Resistance, Microbial; Foscarnet; Herpes Simplex; HIV Seropositivi

1990
Heterotypic and homotypic re-inoculation of mice already latently infected with herpes simplex virus type 1.
    Archives of virology, 1990, Volume: 110, Issue:1-2

    Topics: Animals; Antiviral Agents; Drug Resistance, Microbial; Female; Foscarnet; Herpes Simplex; Mice; Mice

1990
Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data.
    The Journal of infectious diseases, 1990, Volume: 161, Issue:6

    Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Drug Resistance, Microbial; Female; Foscarnet;

1990
Acyclovir-resistant herpes simplex virus causing pneumonia after marrow transplantation.
    The Journal of infectious diseases, 1990, Volume: 162, Issue:1

    Topics: Acyclovir; Adult; Animals; Antiviral Agents; Bone Marrow Transplantation; Cells, Cultured; Drug Resi

1990
Altered sensitivity to antiviral drugs of herpes simplex virus isolates from a patient with the acquired immunodeficiency syndrome.
    The Journal of infectious diseases, 1990, Volume: 162, Issue:3

    Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Aphidicolin; Deoxyguanosine;

1990
Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS). An uncontrolled trial.
    Annals of internal medicine, 1989, May-01, Volume: 110, Issue:9

    Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Drug Resistance, Microbial;

1989
Acyclovir-resistant, foscarnet-sensitive oral herpes simplex type 2 lesion in a patient with AIDS.
    Oral surgery, oral medicine, and oral pathology, 1989, Volume: 67, Issue:4

    Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Candidiasis, Oral; Drug Resi

1989
Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome.
    The New England journal of medicine, 1989, Feb-02, Volume: 320, Issue:5

    Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Drug Resistance, Microbial;

1989
Progressive mucocutaneous herpes simplex infection due to acyclovir-resistant virus in an immunocompromised patient: correlation of viral susceptibilities and plasma levels with response to therapy.
    Diagnostic microbiology and infectious disease, 1987, Volume: 7, Issue:3

    Topics: Acyclovir; Child; Drug Resistance, Microbial; Herpes Simplex; Humans; Keratitis, Dendritic; Male; Ph

1987
Therapeutic effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine, caffeic acid oxidation product, and trisodiumphosphonoformate on cutaneous herpes simplex virus type 1 infection in guinea pigs.
    Journal of medical virology, 1987, Volume: 23, Issue:3

    Topics: Animals; Antiviral Agents; Bromodeoxyuridine; Caffeic Acids; Cinnamates; Female; Foscarnet; Guinea P

1987
Expression of herpes simplex virus type 1 latency-associated transcripts in the trigeminal ganglia of mice during acute infection and reactivation of latent infection.
    Journal of virology, 1988, Volume: 62, Issue:5

    Topics: Animals; Deoxyribonuclease BamHI; DNA Restriction Enzymes; DNA, Viral; Herpes Simplex; Mice; Novobio

1988
Limited efficacy of inhibitors of herpes simplex virus DNA synthesis in murine models of recrudescent disease.
    The Journal of general virology, 1988, Volume: 69 ( Pt 6)

    Topics: Acyclovir; Administration, Oral; Administration, Topical; Animals; Antiviral Agents; Disease Models,

1988
Efficacy of 5-vinyl-1-beta-D-arabinofuranosyluracil (VaraU) against herpes simplex virus type 2 strains in cell cultures and against experimental herpes encephalitis in mice: comparison with acyclovir and foscarnet.
    Pharmaceutical research, 1987, Volume: 4, Issue:3

    Topics: Acyclovir; Animals; Antiviral Agents; Arabinofuranosyluracil; Cells, Cultured; Encephalitis; Female;

1987
Herpes simplex virus hepatitis in mice: effects of treatment with trisodium phosphonoformate.
    Acta virologica, 1985, Volume: 29, Issue:6

    Topics: Animals; Antiviral Agents; Disease Models, Animal; Foscarnet; Hepatitis, Viral, Animal; Herpes Simpl

1985
Comparison of foscarnet cream, acyclovir cream, and acyclovir ointment in the topical treatment of experimental cutaneous herpes simplex virus type 1 infection.
    Antimicrobial agents and chemotherapy, 1986, Volume: 30, Issue:1

    Topics: Acyclovir; Administration, Topical; Animals; Female; Foscarnet; Guinea Pigs; Herpes Simplex; Ointmen

1986
The effects of topical foscarnet in a new model of herpes simplex skin infection.
    The Journal of antimicrobial chemotherapy, 1987, Volume: 20, Issue:4

    Topics: Administration, Cutaneous; Animals; Antiviral Agents; Disease Models, Animal; Foscarnet; Herpes Simp

1987
Structure-activity studies on phosphonoacetate.
    Antimicrobial agents and chemotherapy, 1985, Volume: 27, Issue:2

    Topics: Amino Acids; Animals; Cells, Cultured; Chemical Phenomena; Chemistry; Culture Techniques; Dermatitis

1985
Combination chemotherapy: interaction of 5-methoxymethyldeoxyuridine with trifluorothymidine, phosphonoformate and acycloguanosine against herpes simplex viruses.
    Antiviral research, 1985, Volume: 5, Issue:1

    Topics: Acyclovir; Animals; Antiviral Agents; Deoxyuridine; DNA, Viral; Drug Combinations; Drug Resistance,

1985
HSV1-specific thymidylate kinase activity in infected cells.
    Intervirology, 1985, Volume: 24, Issue:1

    Topics: Acyclovir; Animals; Bromodeoxyuridine; Cells, Cultured; Cricetinae; Deoxyuridine; Drug Resistance, M

1985
Selection and characterisation of acyclovir-resistant herpes simplex virus type 1 mutants inducing altered DNA polymerase activities.
    Virology, 1985, Oct-30, Volume: 146, Issue:2

    Topics: Acyclovir; Animals; Cell Line; Cricetinae; DNA-Directed DNA Polymerase; Drug Resistance, Microbial;

1985
Clinical experiences with phosphonoformate (foscarnet) treatment of viral diseases following renal transplantation.
    Scandinavian journal of urology and nephrology. Supplementum, 1985, Volume: 92

    Topics: Adult; Aged; Antiviral Agents; Cytomegalovirus Infections; Female; Foscarnet; Herpes Simplex; Herpes

1985
Treatment of experimental herpes simplex virus type 1 encephalitis in mice with (E)-5-(2-bromovinyl)- and 5-vinyl-1-beta-D-arabinofuranosyluracil: comparison with bromovinyl-deoxyuridine and acyclovir.
    Antiviral research, 1986, Volume: 6, Issue:2

    Topics: Acyclovir; Animals; Arabinofuranosyluracil; Bromodeoxyuridine; Cells, Cultured; Encephalitis; Female

1986
Anti-herpes virus combinations in relation to drug resistance.
    The Journal of antimicrobial chemotherapy, 1986, Volume: 18 Suppl B

    Topics: Acyclovir; Adenosine Deaminase Inhibitors; Animals; Antiviral Agents; Diphosphates; Drug Resistance,

1986
Nucleoside pools of acyclovir-treated herpes simplex type 1 infected cells.
    Antiviral research, 1985, Volume: 5, Issue:2

    Topics: Acyclovir; Animals; Cells, Cultured; Chlorocebus aethiops; Foscarnet; Herpes Simplex; Humans; Kineti

1985